Novozymes A/S (OTCMKTS:NVZMY) Upgraded at Barclays

Barclays upgraded shares of Novozymes A/S (OTCMKTS:NVZMY) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

NVZMY has been the subject of several other reports. Berenberg Bank raised Novozymes A/S to a “strong-buy” rating in a research report on Tuesday, September 24th. Citigroup cut shares of Novozymes A/S from a “neutral” rating to a “sell” rating in a research note on Thursday, October 17th.

Novozymes A/S Stock Up 1.3 %

OTCMKTS:NVZMY opened at $57.26 on Monday. The company has a market cap of $26.81 billion, a P/E ratio of 36.24, a price-to-earnings-growth ratio of 3.87 and a beta of 0.90. Novozymes A/S has a twelve month low of $49.99 and a twelve month high of $72.50. The business has a 50 day moving average price of $65.64 and a two-hundred day moving average price of $63.83.

Novozymes A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Wednesday, September 18th. Investors of record on Monday, September 9th were paid a $0.1678 dividend. The ex-dividend date of this dividend was Monday, September 9th. Novozymes A/S’s dividend payout ratio (DPR) is currently 41.77%.

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.